To assess the cumulative effect of an enhanced recovery after surgery (ERAS) pathway and minimally invasive robotassisted radical cystectomy with intracorporeal urinary diversion (iRARC) in comparison with open radical cystectomy (ORC) on length of hospital stay (LOS) and perioperative outcomes.
who underwent iRARC with ERAS had a significantly higher American Society of Anesthesiologists score (III-IV) and were more likely to receive neobladder reconstruction. The median (interquartile range) LOS was shorter in the iRARC with ERAS group (7 [6-10] ) days than in the iRARC without ERAS group (11 [8] [9] [10] [11] [12] [13] [14] [15] ) days and the ORC group (17 [14] [15] [16] [17] [18] [19] [20] [21] 
days).
In a propensity score-matched cohort of patients who underwent iRARC, patients who followed the ERAS pathway had significantly lower 90-day readmission rates. Additionally, implementing ERAS in an iRARC cohort resulted in a significantly lower 90-day all (P < 0.001) and gastrointestinalrelated complications (P = 0.001). The ERAS pathway and younger patients were independently associated with an LOS of ≤10 days on multinomial logistic regression.
Introduction
Radical cystectomy is the recommended treatment for muscle-invasive bladder cancer and selected high-risk non-muscle invasive bladder cancer, as set out by international guidelines [1, 2] . Cystectomy is a morbid procedure and associated with a 3% 90-day mortality in highvolume centres [3] . Risk of complications can be attributed to cardiovascular and respiratory comorbidity in an older population with a high prevalence of smoking history.
Efforts to minimize postoperative morbidity include the development of robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (iRARC) and its rapid adoption seeks to replicate the oncological principles of open surgery whilst promoting early return to normal activity. Early oncological outcomes for open radical cystectomy (ORC) and iRARC are similar [4] ; however, a meta-analysis of randomized controlled trials comparing ORC and RARC has failed to show significant differences in overall perioperative outcomes [5] . Although RARC resulted in lower blood loss and lower wound-related complications, there was no difference in 90-day complications nor in length of hospital stay (LOS). Single-institution observation data do suggest a benefit for RARC, but, by definition, reports are from early adopters in high-volume centres and frequently have established peri-operative enhanced recovery after surgery (ERAS) programmes [6] .
The ERAS pathway was initially piloted and evolved for colorectal surgery and has led to reduction in LOS and complications without compromising patient safety [7] . More recently, ERAS has been implemented for radical cystectomy, with reports of reductions in peri-operative complication rates and in LOS to as low as 4 days [8] [9] [10] . ERAS represent a multi-modal peri-operative care pathway designed to expedite postoperative recovery and improve morbidity by minimizing organ dysfunction and reducing the metabolic stress response secondary to surgery.
In the present study, we assess the impact of iRARC as well as the cumulative effect of ERAS and iRARC on the perioperative outcomes of patients undergoing radical cystectomy.
Patient and Methods

Patient Population
Between March 2009 and November 2016, 304 radical cystectomies were performed at a single institution (ORC, n = 54, RARC, n = 250). Data were prospectively collected using an institutional approved database. iRARC has been the default approach to radical cystectomy from 2014, with 98% of cystectomy cases performed using this approach. A structured ERAS pathway was adopted in May 2016. We identified 45 consecutive ORC cases without ERAS which were performed before the introduction of our robotic cystectomy programme (Cohort A), 50 consecutive iRARC cases before the implementation of an ERAS pathway (Cohort B) and 50 consecutive iRARC cases which were performed after the adoption of ERAS (Cohort C). All cases were performed by one of two surgeons. Fifty cases were excluded during the transition period from ORC to iRARC to account for the iRARC learning curve and a further 75 cases were excluded when the current ERAS pathway was gradually implemented (Fig. 1) . This study was part of a quality assurance programme and registered with our intuitional department (Urology2015.2).
Surgical Technique
All patients received either ileal conduit or neobladder reconstruction; this was dependent on patient choice, provided there were no absolute contraindications. A standard approach for ORC and iRARC has been previously described [11, 12] . The Studer neobladder technique was performed for ORC cases. Briefly, iRARC was performed using a standard six-port transperitoneal approach, with 20°T rendelenburg. A standard lymph node dissection template with the following boundaries was used for both ORC and iRARC cases: genitofemoral nerve laterally, ureteric crossing at the common iliac vessels proximally, the circumflex iliac vein and node of Cloquet anteriorly and the hypogastric vessels posteriorly. After RARC and construction of the urinary diversion, the specimen and dissected nodes were placed in an EndoCatch bag (Covidien, Dublin, Ireland) and removed. For patients receiving ileal conduit, a 15-cm segment of ileum 15 cm from the ileal-cecal valve was isolated using a 60-mm Endo-GIA laparoscopic intestinal stapler (Covidien). Intracorporeal neobladder construction was performed using 50 cm of terminal ileum, which was detubularized and cross-folded to form the Pyramid pouch, which is without an afferent limb [11] . A suprapubic and urethral catheter was placed for patients undergoing neobladder reconstruction. Uretero-ileal anastomosis was performed using either Bricker or Wallace anastomosis, depending on surgeon's preference, over 6-F infant feeding tubes. The tubes were externalized and sutured using 3/0 undyed polyglactin 910 sutures (Ethicon, Somerville, NJ, USA), which break down after 10 days and allow the stents to fall out. A pelvic drain was placed and removed when output was <50 mL/24 h. At 6 weeks, a cystogram was performed for patients undergoing neobladder reconstruction prior to removal of the urethral and suprapubic catheter if there was no urinary leak.
Non-ERAS Pathway
All patients received best-of-care practice, with no standardization of preoperative and postoperative care. Patients abstained from food and only had clear fluids for 12 h, up until 2 h before surgery. Bowel preparation was avoided prior to surgery. Intra-operatively, 3000 mL of i.v. fluids were typically prescribed. All patients received epidural analgesia. Postoperative analgesia comprised fentanyl patientcontrolled analgesia (PCA), stepping down onto an oral regime consistent with the WHO analgesic stepladder. The ORC cohort had their nasogastric tube removed 1-2 days postoperatively, provided they were tolerating oral intake. The iRARC cohort had their nasogastric tube removed after surgery. Patients were commenced on a soft diet from day 2, if tolerated. Patient mobilization was dependent on the motivation of individual patients.
Enhanced Recovery after Surgery
The ERAS protocol implemented has been previously described [12] . All patients are seen at a dedicated cystectomy pre-assessment clinic, where they see a surgeon, an anaesthetist and a stoma care nurse, and undergo a cardioplumonary exercise test. Patients are educated about the surgical pathway and patient's goals and expectations are set.
There is no bowel preparation, instead patients are advised to adopt a low-residue diet for 2 days prior to surgery. All patients are provided with two high-calorie carbohydrate drinks to consume before surgery: one at 22:00 h the night before surgery and the second at 06:00 h on the day of surgery. Spinal anaesthesia with 2 mL 0.5% heavy bupivacaine and 1 mg of diamorphine is used as a single-shot neuroaxial block. A transoesophageal Doppler is used for indirect monitoring of cardiac output to aid goal-directed fluid therapy.
After surgery, the nasogastric tube is removed in theatre and all patients are admitted to intensive care. A standard prescribing regime includes: paracetamol; non-steroidal and oral morphine for breakthrough pain, as well as regular pharmacological agents to promote bowel recovery; metoclopramide; magnesium sulphate; and ranitidine. Low molecular weight heparin is administered s.c. 6 h after surgery for 4 weeks postoperatively.
The i.v. fluids are discontinued after surgery. Patients are commenced on oral clear fluids immediately postoperatively, and allowed free fluids orally as tolerated. Oral diet is started on the first postoperative day. Patients are instructed to start an incrementally increasing mobilization regime, starting with a minimum of 20 m three times per day and increasing up to 60 m three times per day immediately. Surgical, anaesthetic, nursing and physiotherapy staff assist patients with initial mobilization, and all teams empower the patient to follow the mobilization regime independently thereafter.
Data Collected
Patient demographics and preoperative variables, including results from the cardioplumonary exercise test, which measures anaerobic threshold (AT), peak oxygen consumption and minute ventilation/carbon dioxide production, as well as American Society of Anesthesiologists (ASA) score, clinical and pathological characteristics, were recorded. Peri-and postoperative data including peri-operative 90-day complications, LOS, readmission and mortality rates, were collected. Postoperative ileus was confirmed on CT scan if there was clinical suspicion. All patients were followed up for a minimum of 90 days after surgery.
Study Outcomes
The primary study endpoint was LOS and the secondary endpoints were 90-day readmission rate and peri-operative complications. Complications were classified using the Clavien-Dindo system.
Statistics
All continuous data, such as mean, median, interquartile range and 95% CI were reported using descriptive statistics. Comparative statistics between categorical variables were reported using the chi-squared test, while a t-test or ANOVA were used for comparison of continuous variables. Multivariable logistic regression was performed to determine the interaction between variables.
To attempt to account for selection bias, a propensity scorematched analysis was performed to adjust for differences in patient characteristics between iRARC-treated patients with or without ERAS. Nearest-neighbour propensity score matching was used to match patients who underwent iRARC with or without ERAS at a 1:1 ratio. Propensity score was determined by modelling logistic regression with the following dependent variables: age; body mass index (BMI); gender; ASA score; and neoadjuvant chemotherapy (NAC) use. Table 1 . Patients in each cohort were evenly matched in age, gender, BMI, NAC, tumour stage, lymph node yield, previous pelvic radiotherapy and surgery, peri-operative anaemia, as well as physiological state (Table 1) . Patients who underwent iRARC with ERAS (Cohort C) had a significantly higher ASA (III-IV) and were more likely to receive neobladder reconstruction (Table 1) . Table 2 shows the data for LOS, 90-day readmission rates, 90-day morbidity and mortality, stratified by cohort. The overall 90-day readmission rate for all patients was 20%, and the 90-day rates for all complications was 57.2% and 22.4% for major complications. Gastrointestinal (GI)-related complications (37.9%) and infection (29.7%) were most common. Wound-related complications were significantly less frequent in iRARC cases than in ORC (5.0% vs 28.6%; P < 0.001).
An iRARC with ERAS (Cohort C) was associated with a shorter LOS compared with ORC or iRARC alone (P < 0.001) and with no associated increase in readmissions compared with Cohorts A and B. Interestingly, the implementation of ERAS resulted in significantly lower 90-day all complications (P < 0.001) and major complications (P = 0.040). GI-related complications were significantly lower in the ERAS group treated with iRARC (18% vs 52%; P < 0.001). The incidence of postoperative ileus was significantly lower in the patients who underwent iRARC with ERAS (Cohort C: 16% vs 34%; P = 0.021). There was no difference in 90-day infection and medical-related complications. A box plot in Fig. 2 shows the LOS distribution of the patient cohort.
After propensity score-matching of iRARC patients to account for gender, age, BMI, ASA and NAC use, patients with ERAS were significantly associated with a lower 90-day admission rate (P = 0.034) and all complications (P = 0.006) and 30-day (P = 0.017) and 90-day (P = 0.002) GI-related complications (Table 3 ). Patients with ERAS had a lower LOS (11.2 vs 14.0 days), although this was not significant.
Multivariable regression confirms that the implementation of an ERAS pathway and younger patient age were independently associated with patient LOS ≤10 days (odds ratio 0.2, 95% CI 0.07-0.57; P = 0.003 [ Table 4 ]). Additionally, multivariable regression showed that ERAS was independently associated with lower 90-day complications (odds ratio 0.17, 95% CI 0.06-0.43; P < 0.001 [ Table 5 ]).
Discussion
The present study is the first to compare postoperative outcomes between patients who have undergone ORC and iRARC with or without an ERAS programme. We report that a structured ERAS protocol results in a decrease in LOS in iRARC-treated patients from a median of 11 to 7 days, without increasing 90-day readmission rates. In patients who did not follow the ERAS pathway, there was a significantly shorter hospital LOS in iRARC compared with ORC, but it was the implementation of ERAS that augmented the benefits of iRARC and significantly improving peri-operative outcomes. Furthermore, an ERAS protocol was independently associated with LOS <10 days, while a minimally invasive robot-assisted approach was not.
Historic reports of ORC performed at high-volume institutions reported a 58-64% 90-day complication rate after surgery, with a 13-22% major complication rate [13, 14] . Previously, we reported a 90-day all and major complication rate of 72% and 21%, respectively, with a median hospital LOS of 10.5 days in 134 consecutive iRARC cases [15] . According to UK and USA population data, the mean LOS after cystectomy before the advent of ERAS was 19 and 11 days, respectively [16, 17] . Evidence from the implementation of ERAS protocols in ORC has shown shorter LOS, while complication and readmission rates have remained constant [8] . In the present study, we observed similar findings in our iRARC patient cohort.
Patient characteristics across our three patient cohorts were similar. The only exception was that patients in Cohort C (iRARC with ERAS) were more likely to have an ASA score ≥III and to undergo neobladder urinary diversion. Despite the potential disadvantage of increased anaesthetic risk, and more complex urinary diversion, patients in this cohort had a significantly lower LOS compared with the non-ERAS cohort of ORC and iRARC, which is testament of the advantages of an ERAS programme. The mean AT of 10.5 suggests that most patients treated had a poor physiological reserve, and that all patients regardless of comorbidity would benefit from the implementation of an ERAS programme.
In a propensity score-matched cohort of patients treated with iRARC adjusted for gender, age, BMI, ASA score and NAC use, the introduction of ERAS reduced LOS from a median of 11 to 7 days, while the significantly lowering of the 90-day readmission rate suggests that patients were discharged home in a safe and timely manner. In addition, patients who followed the ERAS pathway had a significantly lower rate of 90-day complications as well as a reduction in the incidence of ileus and subsequent GI-related complications, which are recognized as a cause of prolonged hospital admission. The ERAS pathway, promotes early mobilization and early introduction of oral intake, as well as the preference for nonsteroidal analgesia over opiate-based analgesia, all of which contribute towards early return to bowel function. As evidenced by data from a randomized controlled trial, the adoption of spinal analgesia as part of an ERAS programme and avoidance of epidural and PCA improves early mobilization providing adequate pain control as well as freedom from PCA pump attachment [18] . Epidural anaesthesia requires continuous i.v. fluids, which can lead to crystalloid overload, resulting in oedematous bowel because of third-spacing which contributes to the developmental of ileus. Additionally, patients also mobilize less as a result of attachment to i.v. lines. Not surprisingly, ORC-treated Table 3 Details of patient length of stay, morbidity and mortality after propensity score matching to account for gender, age, body mass index, American Society of Anesthesiologists score and neoadjuvant chemotherapy use. ERAS, enhanced recovery after surgery; GI, gastrointestinal; IQR, interquartile range; iRARC, minimally invasive robot-assisted radical cystectomy with intracorporeal urinary diversion; LOS, length of hospital stay. patients had significantly more wound complications than iRARC-treated patients, which is also consistent with data from a meta-analysis [5] .
The present results are consistent with other reported outcomes after implementation of an ERAS pathway for RARC [9, 10, 19] . A median LOS of 7-8 days is reported and avoidance of PCA has been highlighted as a major factor influencing LOS. Although our preference is for spinal analgesia, the use of oxycodone is described by others [9, 10, 19] . The European Association of Urology Robotic Section Scientific Working Group recently published consensus for enhanced recovery for RARC in efforts to guide the standardization of postoperative care [20] .
Previous studies have not reported 90-day complication rates, and instead report 30-day all and major complication rates, ranging from 31 to 57%, and 9 to 18%, respectively, with a 30-day readmission rate of 3-33% (Table 6) [9, 10, 19] . In this series, we report a 90-day all and major complication rate of 42% and 12%, with a 12% 90-day readmission. Our reported 30-day complication and readmission rates are similar to other reported series.
We performed a multivariate analysis to identify factors associated with LOS ≤10 days. ASA scores ≥III and elevated BMI as well as the technique of (open vs robot-assisted) were not predictors of hospital LOS ≤10 days. In the iRARC + ERAS cohort, 24% of patients had LOS >10 days and this was associated with the development of 30-and 90-day complications. We have previously reported that patients with significant risk factors, such as preoperative anaemia [21] , and poor cardio-respiratory reserve [22] were not at increased risk of developing complications after an iRARC procedure. We identified that age and ERAS were independently associated with a reduction in LOS.
Within ERAS, there are multiple components which may influence the outcomes and can be considered as marginal gains, representing small improvements in multiple areas that cumulatively result in significant benefit. As such, it is necessary to introduce the pathway as an all-or-nothing approach, and our results suggest a significant gain. Similarly, the robot-assisted approach has multiple components which collectively can potentiate recovery; however, the impact of this alone has not been reported as level 1 evidence.
The present study has important limitations. Firstly, the patient cohort size was limited and represents an evolution of an optimized cystectomy programme. While outcomes of the patients who underwent iRARC in this cohort were prospectively recorded, the ORC cohort represents a historic cohort which was formed before centralization of cystectomy services, and the data collected were retrospective. It is worth noting that although ERAS was associated with the significant gains seen, other factors such as centralization of services and learning curve may account for the decrease in morbidity reported. The ORC cohort was performed pre-centralization and while the Pasadena Consensus suggests that the learning curve for RARC is approximately 30 cases, despite excluding our first 50 iRARC cases, surgical technical ability may Table 6 Comparison of the present study with other trials.
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Koupparis et al. [10] Miller et al. [9] Collins et al. [19] Number continue to improve beyond this [23] . Because of the retrospective nature of the data on ORC cases, the 30-day readmission rate may be under-represented. Interestingly, 15.6% (7/45 patients) of patients who underwent ORC had an LOS ≥30 days, compared with 6% (3/50 patients) and 4% (2/50 patients) in the iRARC and iRARC with ERAS patient cohorts.
In conclusion, these data suggest that ERAS is an independent factor associated with hospital LOS ≤10 days and that the surgical approach (iRACR or ORC) was not.
Patients undergoing ORC, however, had a significantly longer LOS compared with those undergoing iRARC alone or iRARC with ERAS. These results suggest that the impact of ERAS can be a confounding factor when interpreting surgical outcome reports after robot-assisted surgery. 
